---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-040826"
form_type: "8-K"
ticker: "ADPT"
cik: "0001478320"
company_name: "Adaptive Biotechnologies Corp"
filed_at: "2021-08-04T23:59:59+00:00"
generated_at: "2026-06-29T22:31:19.784175+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Adaptive Biotechnologies Q2 revenue $38.5M, +83% YoY; raises FY2021 guidance to $148M-$155M

## Summary
- Revenue $38.5M (+83% YoY); sequencing revenue $18.6M (+132%), development revenue $20.0M (+53%).
- Net loss $49.3M vs $33.5M YoY; adjusted EBITDA loss $35.6M vs $28.5M.
- FY2021 revenue guidance raised to $148M-$155M (prior $145M-$155M).
- clonoSEQ volume +75% YoY; signed agreements with Vaccibody and Moderna for T-cell data and COVID vaccine T-cell response measurement.
- Cash and marketable securities $689.5M as of June 30, 2021.

## SEC filing metadata
- accession: 0001564590-21-040826
- form_type: 8-K
- ticker: ADPT
- cik: 0001478320
- company_name: Adaptive Biotechnologies Corp
- filed_at: 2021-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1478320/000156459021040826/0001564590-21-040826-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1478320/000156459021040826/adpt-8k_20210804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-040826
- JSON: https://secwatch.observer/filing/0001564590-21-040826.json
- Plain text: https://secwatch.observer/filing/0001564590-21-040826.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.